NCT00567710View on ClinicalTrials.gov

A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study

PHASE2CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

September 30, 2009

Conditions
Schizophrenia
Interventions
DRUG

BL - 1020

10 mg/day

DRUG

BL - 1020

BL 1020 20-30 mg/day

DRUG

Placebo

Capsules

DRUG

Risperidone

Capsules

Trial Locations (1)

75062

Mary ann Knisevich, Irving

Sponsors

Lead Sponsor

BioLineRx, Ltd.
All Listed Sponsors
lead

BioLineRx, Ltd.

INDUSTRY

NCT00567710 - A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study | Biotech Hunter | Biotech Hunter